Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...

Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to data presented at the American College of Allergy, Asthma & Immunology Annual ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...

Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard treatment, have failed. Some patients with CSU experience intense itching, ...

Here are the top 5 AJMC.com articles and videos on allergy for 2025.

A multicentre retrospective study has found that chronic spontaneous urticaria (CSU) occurring in patients with systemic ...

Doctors call it "urticaria," but everyone else calls it "hives." We're talking about the incredibly itchy, swollen rash that can suddenly show up on skin, without warning, only to disappear and show ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

NPC is an ultra-rare, relentlessly progressive, genetic disorder that leads to premature mortality. MIPLYFFA, used in conjunction with miglustat, is the only treatment shown to halt disease ...

The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...